Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by SanFrancisco99on Nov 16, 2017 5:52pm
280 Views
Post# 26980214

RE:RE:RE:Aureus Thread on IV

RE:RE:RE:Aureus Thread on IVWell, I'd be happy with an offer from any camp as long as they pay for the value.

One other thing about the chance meeting between Don and the Glaxo exec in the hallway, I specifically remember the Glaxo executive saying "We'd like to buy your company for $10billion."   To which Don replied, "Sounds good".   Then the Glaxo exec said:  "But we have to wait until November 17, 2017 due to some funds we have that will be freed up that day."   Don replied:   "Wonderful.   Let's shake."   And then, they shook hands and someone presented a contract that I was able to glance over as I walked by.  It seemed to have all the relevant terms in it under the bold heading "IRREVERSIBLE TEN BILLION DOLLAR CONTRACT."

And.....

Oh wait, I just woke up from my daydrean.   Yes, I'm kidding about everything in this post except the first sentance.  

Sorry, couldn't resist.

SF
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities